Philochem is open to partnerships that are in line with the company’s corporate strategy to continue the development of its preclinical and clinical programs and to develop and advance its technology platforms.

Philochem offers collaborations based on its proprietary small molecule ligands for pharmacodelivery and will selectively choose to partner with companies that have therapeutic expertise in relevant disease areas and a significant commitment to the development and commercialization of targeted drugs.

In addition, Philochem offers attractive fee-for-service collaborations using the following platform technologies:

For collaboration opportunities, partnerships, or licensing agreements, please contact:


Collaboration on DNA-Encoded Chemical Libraries

Philochem has pioneered the development of the DNA-Encoded Chemical Library (DECL) technology, which opens new possibilities for drug discovery in a fast and cost-effective way. Philochem owns proprietary technologies and large DNA-encoded chemical libraries containing more than one billion compounds.

We offer flexible collaboration structures, adjusted to the requirements of the partner, for the screening of binders against few or several targets of choice. For more information, please visit: Enabling Technologies: 1. DNA-Encoded Chemical Libraries


A wealth of partnerships validate our approach and science

The Philogen Group has signed collaboration and/or licensing agreements with large pharmaceutical companies including AbbVie, Bayer, Boehringer Ingelheim, Celgene (a subsidiary of Bristol-Myers Squibb), Janssen Biotech, Inc. (a Johnson & Johnson company), MedImmune (a wholly owned subsidiary of AstraZeneca), Merck-Serono, Novartis, Pfizer, Schering and Servier

Our collaboration agreements with academic institutions include ETH Zurich, Scripps Research, The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ), University of Zurich and Wyss Translational Center Zurich